Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?

Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?

Author Peres, Fernanda Fiel Autor UNIFESP Google Scholar
Lima, Alvaro C. Google Scholar
Hallak, Jaime E. C. Google Scholar
Crippa, José Alexandre de Souza Autor UNIFESP Google Scholar
Silva, Regina Helena da Autor UNIFESP Google Scholar
Abilio, Vanessa Costhek Autor UNIFESP Google Scholar
Abstract Movement disorders such as Parkinson's disease and dyskinesia are highly debilitating conditions linked to oxidative stress and neurodegeneration. When available, the pharmacological therapies for these disorders are still mainly symptomatic, do not benefit all patients and induce severe side effects. Cannabidiol is a non-psychotomimetic compound from Cannabis sativa that presents antipsychotic, anxiolytic, anti-inflammatory, and neuroprotective effects. Although the studies that investigate the effects of this compound on movement disorders are surprisingly few, cannabidiol emerges as a promising compound to treat and/or prevent them. Here, we review these clinical and pre-clinical studies and draw attention to the potential of cannabidiol in this field.
Keywords cannabidiol
movement disorders
Parkinson's disease
Huntington's disease
dystonic disorders
cannabinoids
Language English
Sponsor Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, Brazil)
Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)
Fundacao de Apoio ao Ensino, Pesquisa e Assistencia do Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto da Universidade de Sao Paulo (FAEPA, Brazil)
Center for Interdisciplinary Research on Applied Neurosciences (NAPNA), University of Sao Paulo, Sao Paulo, Brazil (NAPNA)
National Institute for Translational Medicine (INCT-TM)
National Institute for Translational Medicine (CNPq/FAPESP, Brazil)
University Global Partnership Network (UGPN)-Global priorities in cannabinoid research excellence
Date 2018
Published in Frontiers In Pharmacology. Lausanne, v. 9, p. -, 2018.
ISSN 1663-9812 (Sherpa/Romeo, impact factor)
Publisher Frontiers Media Sa
Extent -
Origin http://dx.doi.org/10.3389/fphar.2018.00482
Access rights Open access Open Access
Type Revisão
Web of Science ID WOS:000431876000001
URI http://repositorio.unifesp.br/handle/11600/46042

Show full item record




File

Name: WOS000431876000001.pdf
Size: 830.8Kb
Format: PDF
Description:
Open file

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account